Funder
Center for Regulatory Excellence in Regulatory Science
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference12 articles.
1. US Food and Drug Administration New Molecular Entity (NME) Drug and New Biologic Approvals. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm. Published September 1, 2015. Accessed January 6, 2017.
2. Philippidis A. The top 15 best-selling drugs of 2016. Genetic Engineering and Biotechnology News. https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868. Published March 2, 2017. Accessed December 24, 2017.
3. Downing NS, Aminawung JA, Shah ND, et al. Regulatory review of novel therapeutics—comparison of three regulatory agencies. N Engl J Med. 2012;366(24):7.
4. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311(4):368-377.
5. Ogasawara K, Breder CD, Lin DH, Alexander GC. Exposure- and dose-response analyses in dose selection and labeling of FDA-approved biologics. Clin Ther. 2018;40(1):95-102.e2.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献